VEGF antibodies, when used alongside a tumor vaccine that promotes granulocyte–macrophage colony-stimulating factor secretion, have been shown to reduce the quantity of CD4 + CTLs and enhance vaccine efficiency [71]. This evidence concerns the gene CD4 and neoplasm.